<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03158610</url>
  </required_header>
  <id_info>
    <org_study_id>BIG-MOON</org_study_id>
    <nct_id>NCT03158610</nct_id>
  </id_info>
  <brief_title>Biological-guided Metronomic Chemotherapy as Maintenance Strategy in Metastatic Colorectal Cancer</brief_title>
  <official_title>Biological-guided Metronomic Chemotherapy as Maintenance Strategy in Responders After Induction Therapy in Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based upon biological behavior, those mCRC patients who respond well (SD, PR or CR according&#xD;
      to RECIST Criteria) after 16-18 weeks of standard doublet chemotherapy as induction may&#xD;
      enrolled into this study, randomly divided into capecitabine metronomic group or standard&#xD;
      dosage group. The duration of disease control after randomization(PFS2) and progression free&#xD;
      survival from enrollment (PFS1) are primary endpoints. Meanwhile, the overall survival,&#xD;
      safety and quality of life are secondary endpoints. Exploratory markers involving&#xD;
      angiogenesis (serum VEGF, PDGF, Tie-1 and Tie2, etc) and immune function (CD clusters, serum&#xD;
      tumor mutation burden(TMB), etc), are conducted via liquid biopsy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is try to evaluate the effect of capecitabine metronomic chemotherapy as&#xD;
      maintenance treatment, which compare to capecitabine conventional chemotherapy, who have&#xD;
      responded to 16-18 months first-line chemotherapy in metastatic colorectal cancer (mCRC). The&#xD;
      maintenance treatments are continued until disease progression or severe toxicity. The aim of&#xD;
      this study is to demonstrate that capecitabine metronomic chemotherapy is non-inferior to&#xD;
      capecitabine conventional chemotherapy. Furthermore, exploratory markers involving&#xD;
      angiogenesis (serum VEGF, PDGF, Tie-1 and Tie2, etc) and immune function (CD clusters, serum&#xD;
      tumor mutation burden(TMB), etc), are conducted via liquid biopsy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficult to enrollment patient&#xD;
  </why_stopped>
  <start_date type="Actual">January 29, 2018</start_date>
  <completion_date type="Actual">April 28, 2021</completion_date>
  <primary_completion_date type="Actual">April 28, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival 1 (PFS1)</measure>
    <time_frame>10 months</time_frame>
    <description>from enrollment to progression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression Free Survival 2 (PFS2)</measure>
    <time_frame>4 months</time_frame>
    <description>from randomization to progression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>20 months</time_frame>
    <description>from signing informed consent to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>20 months</time_frame>
    <description>drug related toxicity from signing informed consent to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with quality of life (QoL) as assessed by CTCAE v4.0</measure>
    <time_frame>20 months</time_frame>
    <description>QoL from signing informed consent to death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Capecitabine metronomic chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capecitabine 500mg/m2 bid po qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Capecitabine standard dosage chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Capecitabine 1000mg/m2 bid po d1-d14,q3w</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Oral fluorouracil</description>
    <arm_group_label>Capecitabine metronomic chemotherapy</arm_group_label>
    <arm_group_label>Capecitabine standard dosage chemotherapy</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Before the start of induction therapy:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological proof of colorectal cancer (in case of a single metastasis, histological&#xD;
             or cytological proof of this lesion should be obtained);&#xD;
&#xD;
          -  Distant metastases which are unresectable (patients with only local recurrence are not&#xD;
             eligible);&#xD;
&#xD;
          -  Measurable disease (&gt; 1 cm on spiral CT scan or &gt; 2 cm on chest X-ray; liver&#xD;
             ultrasound is not allowed). Serum CEA may not be used as a parameter for disease&#xD;
             evaluation;&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Prior adjuvant treatment for stage II/III colorectal cancer ending within 6 months&#xD;
             before the start of induction treatment&#xD;
&#xD;
          -  Any prior adjuvant treatment after resection of distant metastases&#xD;
&#xD;
          -  Previous systemic treatment for advanced disease&#xD;
&#xD;
        At randomisation:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  WHO performance status 0-1 (Karnofsky PS &gt; 70%);&#xD;
&#xD;
          -  Disease evaluation with proven SD, PR or CR according to RECIST after first-line&#xD;
             induction treatment;&#xD;
&#xD;
          -  Laboratory values obtained ≤ 2 weeks prior to randomisation: adequate bone marrow&#xD;
             function (Hb &gt; 6.0 mmol/L, absolute neutrophil count &gt; 1.5 x 109/L, platelets &gt; 100 x&#xD;
             109/L), renal function (serum creatinine ≤ 1.5x ULN and creatinine clearance, Cockroft&#xD;
             formula, &gt; 30 ml/min), liver function (serum bilirubin ≤ 2 x ULN, serum transaminases&#xD;
             ≤ 3 x ULN without presence of liver metastases or ≤ 5x ULN with presence of liver&#xD;
             metastases);&#xD;
&#xD;
          -  Life expectancy &gt; 12 weeks;&#xD;
&#xD;
          -  Age: 18-75 years;&#xD;
&#xD;
          -  Negative pregnancy test in women with childbearing potential;&#xD;
&#xD;
          -  Expected adequacy of follow-up;&#xD;
&#xD;
          -  Institutional Review Board approval;&#xD;
&#xD;
          -  Written informed consent Exclusion criteria&#xD;
&#xD;
          -  Chronic active infection;&#xD;
&#xD;
          -  Any other concurrent severe or uncontrolled disease preventing the safe administration&#xD;
             of study drugs;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Zhang, MD &amp; Ph. D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Oncology, Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Kareva I, Waxman DJ, Lakka Klement G. Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance. Cancer Lett. 2015 Mar 28;358(2):100-106. doi: 10.1016/j.canlet.2014.12.039. Epub 2014 Dec 23. Review.</citation>
    <PMID>25541061</PMID>
  </reference>
  <reference>
    <citation>Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, Mineur L, Carola E, Etienne PL, Rivera F, Chirivella I, Perez-Staub N, Louvet C, André T, Tabah-Fisch I, de Gramont A. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study. J Clin Oncol. 2006 Jan 20;24(3):394-400.</citation>
    <PMID>16421419</PMID>
  </reference>
  <reference>
    <citation>André T, Tournigand C, Mineur L, Fellague-Chebra R, Flesch M, Mabro M, Hebbar M, Postel Vinay S, Bidard FC, Louvet C, de Gramont A. Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study. Ann Oncol. 2007 Jan;18(1):77-81. doi: 10.1093/annonc/mdl336. Epub 2006 Oct 9.</citation>
    <PMID>17030548</PMID>
  </reference>
  <reference>
    <citation>Simkens LH, van Tinteren H, May A, ten Tije AJ, Creemers GJ, Loosveld OJ, de Jongh FE, Erdkamp FL, Erjavec Z, van der Torren AM, Tol J, Braun HJ, Nieboer P, van der Hoeven JJ, Haasjes JG, Jansen RL, Wals J, Cats A, Derleyn VA, Honkoop AH, Mol L, Punt CJ, Koopman M. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet. 2015 May 9;385(9980):1843-52. doi: 10.1016/S0140-6736(14)62004-3. Epub 2015 Apr 7.</citation>
    <PMID>25862517</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 15, 2017</study_first_submitted>
  <study_first_submitted_qc>May 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2017</study_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Jun Zhang</investigator_full_name>
    <investigator_title>Deputy-chief of Department of Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

